(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 39.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Regenxbio's revenue in 2026 is $170,441,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $13,301,698,236, with the lowest RGNX revenue forecast at $6,828,913,913, and the highest RGNX revenue forecast at $21,081,323,315. On average, 12 Wall Street analysts forecast RGNX's revenue for 2027 to be $15,840,024,790, with the lowest RGNX revenue forecast at $8,039,238,388, and the highest RGNX revenue forecast at $29,075,142,277.
In 2028, RGNX is forecast to generate $25,824,556,544 in revenue, with the lowest revenue forecast at $17,799,769,792 and the highest revenue forecast at $35,296,571,368.